Ruijie Xiao

Ruijie Xiao

Auto-generated profile, based on publicly available information

Ruijie Xiao

Xiangya School of Medicine, Central South University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in eClinicalMedicine
Verified
Journal Article
Open access
RXRuijie Xiao
Ruijie Xiao
PTPeiyuan Tang
Peiyuan Tang
JZJing Zhou
Jing Zhou
WZWeiyue Zheng
Weiyue Zheng
YCYangbin Cao
Yangbin Cao
Yusheng LiYusheng Li
Yusheng Li
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disorder that is characterized by progressive synovial inflammation and leads to joint destruction, functional decline, and reduced life expectancy. Although tumor necrosis factor-alpha inhibitors (TNFi) have revolutionized RA management by preventing structural damage, their safety profiles remain controversial. Current safety assessments remain fragmented across isolated meta-analyses, failing to address competing risks or incorporate recent pharmacovigilance data. This study compared the adverse effects of anti-TNF therapy in RA and provided a stratified safety profile for optimal treatment selection. The research team searched four databases, namely PubMed, Web of Science, EMBASE, and the Cochrane Library, for relevant articles published from January 2000 to March 2025. The review adhered rigorously to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. For each meta-analysis, we recalculated effect sizes as either odds ratio (OR), relative risk (RR) or standardized mean differences (SMD), accompanied by their respective 95% confidence intervals (CIs). Methodological quality of included meta-analyses was evaluated with A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2), while the certainty of evidence was assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. To address potential overlap among primary studies across meta-analyses, the investigators utilized the Graphical Representation of Overlap for Overviews (GROOVE) tool, followed by classification of the synthesized evidence into four levels based on predefined criteria. This umbrella review was prospectively registered on PROSPERO (CRD42025638409). We synthesized results from 12 meta-analyses. The result indicated that TNF-α inhibitor therapy in RA patients was associated with (a) significantly increased risk of serious infection (OR = 1.63, 95% CI: 1.31, 2.04, p < 0.001, I2 = 3%); (b) reduced risks of all cardiovascular events (RR = 0.60, 95% CI: 0.40, 0.89, p = 0.01, I2 = 54%), myocardial infarction (RR = 0.75, 95% CI: 0.58, 0.98, p = 0.03, I2 = 29%); and insulin resistance (SMD = -0.82, 95% CI: -1.38, -0.25, p < 0.01, I2 = 92%). However, no significant associations were observed for malignant tumors (OR = 1.22, 95% CI: 0.83, 1.79, p = 0.30, I2 = 0%) or insulin sensitivity (SMD = 1.31, 95% CI: -0.34, 2.96, p < 0.01, I2 = 93%). Substantial heterogeneity existed in all main analyses. TNF-α inhibitors are potentially associated with a higher risk of serious infection, while may have beneficial effects on cardiovascular events, myocardial infarction and insulin resistance but no association was found with other indications. However, the inconsistent methodological across studies reduces statistical power and limits the reliability of these findings, which must be interpreted cautiously. This work was supported by National Key R&D Program of China (No. 2023YFB4606705), National Natural Science Foundation of China (No. 82272611, 82472522, 82072506 and 92268115), Hunan Provincial Science Fund for Distinguished Young Scholars (No. 2024JJ2089), Science and Technology Innovation Program of Hunan Province (No. 2023SK2024) and Natural Science Foundation of Hunan Province (No. 2023JJ30949).

22 December 2025 in Annals of Medicine
Verified
Journal Article
Open access
PTPeiyuan Tang
Peiyuan Tang
RXRuijie Xiao
Ruijie Xiao
WXWenfeng Xiao
Wenfeng Xiao
TWTing Wen
Ting Wen
YLYusheng Li
Yusheng Li
XYXucheng Yang
Xucheng Yang
Recent reports suggest that the COVID-19 pandemic and associated lockdowns may have influenced the epidemiology of osteoporotic fractures, but results vary across regions and fracture types. The aim of this study was to provide evidence-based insights into the impact of the pandemic on osteoporotic fracture incidence. We searched four databases (PubMed, Embase, Cochrane Library, and Web of Science) up to August 2025 for observational or retrospective studies comparing osteoporotic fracture incidence during the COVID-19 pandemic (2020) with the pre-pandemic period (2019). The primary outcome of interest was the change in fracture incidence, analysed using risk ratios (RR) with 95% confidence intervals (CI) in Review Manager 5.4. Subgroup analyses were performed by sex, geographic region, and fracture type. Nine studies meeting the inclusion criteria were analysed. Overall, "all types" of osteoporotic fractures showed a significant decrease during the pandemic (RR = 0.85, 95% CI 0.80-0.91, p < 0.0001). Specifically, forearm fractures decreased significantly (RR = 0.87, 95% CI 0.79-0.96, p = 0.002). However, for the most clinically significant fractures, no statistically significant global change was found for hip fractures (RR = 0.93, 95% CI 0.76-1.15, p = 0.14) or vertebral fractures (RR = 1.35, 95% CI 0.85-2.15, p = 0.20). In regional subgroup analysis, hip fracture incidence decreased significantly in South America (RR = 0.79, p = 0.0004) and in both males and females, but no significant change was observed in Europe (RR = 0.92, 95% CI 0.81-1.04, p = 0.17). During the COVID-19 pandemic, there was a decrease in the incidence of minor fractures, such as those of the forearm, likely due to reduced outdoor activity. However, the incidence of major osteoporotic fractures (hip and vertebral) remained stable globally, with significant reductions observed only in specific regions like South America.